Compounds > atazanavir sulfate
Page last updated: 2024-09-04

atazanavir sulfate and Body Weight

atazanavir sulfate has been researched along with Body Weight in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nzuza, S; Owira, PMO; Zondi, S1
Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Riva, A; Rizzardini, G1
Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gazzard, B; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Sabin, C; Stöhr, W; Winston, A1
Bertz, R; Hong, Y; Horga, M; Kowalski, KG; Pfister, M; Roy, A; Zhang, J; Zhu, L1
Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Herrington, JD; Maclayton, DO; Nguyen, ST; Payne, KD; Rahman, AP; Rodriguez-Barradas, MC1

Other Studies

5 other study(ies) available for atazanavir sulfate and Body Weight

ArticleYear
Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Atazanavir Sulfate; Blood Glucose; Body Weight; Caspase 3; Caspase 9; Drinking; Fasting; Flavanones; Glucokinase; Glucose Intolerance; HIV Protease; HIV Protease Inhibitors; Homeostasis; Insulin; Insulin Resistance; Liver; Male; Metabolic Syndrome; Pancreas; Rats, Wistar; Saquinavir; Signal Transduction; Uncoupling Protein 2

2017
Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
    Antiviral therapy, 2015, Volume: 20, Issue:4

    Topics: Adult; Age Factors; Atazanavir Sulfate; Body Weight; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Ritonavir; Rosuvastatin Calcium; Sex Factors; Viral Load

2015
Factors influencing lopinavir and atazanavir plasma concentration.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Weight; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrimidinones; Rifabutin; United Kingdom

2010
Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Weight; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Models, Biological; Oligopeptides; Pediatrics; Practice Guidelines as Topic; Pyridines; Treatment Outcome

2011
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Pharmacotherapy, 2008, Volume: 28, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Mass Index; Body Weight; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir

2008